Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's Covid-19 vaccine after more than a month of delay b

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who have at least one underlying condition that puts them at higher risk of severe illness.

The FDA announced yesterday that it will limit access to Covid-19 vaccines to people 65 years of age and older and others who are at high risk of becoming seriously ill. It will also require manufacturers to conduct clinical trials to show whether the vaccines benefit healthy younger adults and children.